Treatment of advanced disease and new drugs.
Frustaci
Sergio
S
Medical Oncology Department, Centro di Riferimento Oncologico (CRO), Istituto Nazionale Tumori, Aviano, Italy. strustaci@cro.it
Buonadonna
Angela
A
La Mura
Nicoletta
N
Berretta
Massimiliano
M
De Paoli
Antonino
A
D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002166:Camptothecin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000069287:Capecitabine; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000077143:Docetaxel; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D000077146:Irinotecan; D009944:Organoplatinum Compounds / Q000627:therapeutic use; D000077150:Oxaliplatin; D017239:Paclitaxel / Q000031:analogs & derivatives* / Q000627:therapeutic use; D013274:Stomach Neoplasms / Q000188:drug therapy*; D043823:Taxoids; D059004:Topoisomerase I Inhibitors
D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D000972:Antineoplastic Agents, Phytogenic; D004791:Enzyme Inhibitors; D009944:Organoplatinum Compounds; D043823:Taxoids; D059004:Topoisomerase I Inhibitors; D000077150:Oxaliplatin; D003841:Deoxycytidine; D000077143:Docetaxel; D000069287:Capecitabine; D000077146:Irinotecan; D017239:Paclitaxel; D005472:Fluorouracil; D002166:Camptothecin